Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly)

PFE 25.04

+2.6%

Nov 21 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Anthony Wong who wrote (277)	6/11/1998 11:07:00 AM
From: Anthony Wong	Read Replies (1) of 1722

DuPont Merck Files FDA Application for HIV Drug Sustiva June 11, 1998 10:18 AM FDA Designates As Fast-Track Drug By Otesa Middleton WASHINGTON (Dow Jones)--DuPont Merck Pharmaceutical Co. submitted to the Food and Drug Administration Thursday a new drug application Thursday for the company's once-a-day HIV drug Sustiva. The FDA, which designated Sustiva a fast-track drug, plans to make a decision on the product within six months. DuPont & Co. (DD) announced last month that it will buy Merck & Co.'s (MRK) 50% interest in their DuPont Merck venture. The deal, expected to close July 1 will make Sustiva, if approved, the first HIV drug of the new DuPont Pharmaceuticals Co.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next